Scholarlink

Purpose <p>Fluorescence is used in various surgical fields to detect tissue ischemia. However, its use in obesity surgery is still limited. This study aims to investigate whether fluorescence can change surgical decisions during metabolic and bariatric surgery. The primary objective was to determine the proportion of patients with abnormal blood flow assessed by fluorescence and changes in intraoperative strategy. The second outcome measured was the morbidity and mortality within 30 days.</p> Methods <p>This single-centre, prospective observational study analysed patients who underwent primary metabolic and bariatric surgery. Data was collected from 66 consecutive patients who qualified for primary one anastomosis gastric bypass and Roux-en-Y gastric bypass procedures.</p> Results <p>In total, improper blood supply was observed in two cases, and surgical strategy was changed in 5.8% of OAGB and 2% of RYGB. No leakage incidents were reported. One patient (1.5%) experienced non-ischemic-related complications. No mortality was observed 30 days after the surgical procedures. No complications related to ICG administration were observed.</p> Conclusion <p>Despite the low incidence of tissue ischemia during metabolic and bariatric surgery, adding ICG fluorescence may potentially impact intraoperative surgical decisions due to ischemia detection during metabolic and bariatric surgery. However, this field lacks systematic data, and further research with a larger patient group is necessary to establish conclusive evidence.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The usefulness of fluorescence in decision-making strategy during bariatric and metabolic surgery

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月24日

查看全文
  • Mateusz Wityk,
  • Michał R. Janik,
  • Maciej Bobowicz,
  • Natalia Dowgiałło-Gornowicz

摘要

Purpose

Fluorescence is used in various surgical fields to detect tissue ischemia. However, its use in obesity surgery is still limited. This study aims to investigate whether fluorescence can change surgical decisions during metabolic and bariatric surgery. The primary objective was to determine the proportion of patients with abnormal blood flow assessed by fluorescence and changes in intraoperative strategy. The second outcome measured was the morbidity and mortality within 30 days.

Methods

This single-centre, prospective observational study analysed patients who underwent primary metabolic and bariatric surgery. Data was collected from 66 consecutive patients who qualified for primary one anastomosis gastric bypass and Roux-en-Y gastric bypass procedures.

Results

In total, improper blood supply was observed in two cases, and surgical strategy was changed in 5.8% of OAGB and 2% of RYGB. No leakage incidents were reported. One patient (1.5%) experienced non-ischemic-related complications. No mortality was observed 30 days after the surgical procedures. No complications related to ICG administration were observed.

Conclusion

Despite the low incidence of tissue ischemia during metabolic and bariatric surgery, adding ICG fluorescence may potentially impact intraoperative surgical decisions due to ischemia detection during metabolic and bariatric surgery. However, this field lacks systematic data, and further research with a larger patient group is necessary to establish conclusive evidence.